Wells Fargo analyst Derek Archila raised the firm’s price target on Dice Therapeutics (DICE) to $48 from $38 and keeps an Equal Weight rating on the shares following news that Eli Lilly (LLY) will acquire the company for $48/share. The deal is expected to close in Q3 and the firm sees modest FTC risk to the deal given some small overlaps, but the deal likely gets done.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DICE:
- DICE Surges after $2.4 Billion Acquisition by LLY
- Eli Lilly to acquire Dice Therapeutics for $48 per share in cash
- Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
- DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
- DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
